MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Search

Arbutus Biopharma Corp

Suletud

4.61 -2.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.59

Max

4.71

Põhinäitajad
By Trading Economics
Sissetulek	4M -3.8M
Müük	522K 1.1M
Aktsiakasum	-0.014
Kasumimarginaal	-357.374
Töötajad	19
EBITDA	75K -7.6M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. mai 2026

Turustatistika
By TradingEconomics
Turukapital	16M 854M
Eelmine avamishind	6.73
Eelmine sulgemishind	4.61

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. apr 2026, 23:49 UTC

Uudisväärsed sündmused

New Zealand 1Q Inflation Higher Than Expected

20. apr 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20. apr 2026, 22:53 UTC

Suurimad hinnamuutused turgudel

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20. apr 2026, 23:45 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20. apr 2026, 23:44 UTC

Market Talk

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20. apr 2026, 23:39 UTC

Market Talk

Rio Tinto Posts Strong Start to Year -- Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20. apr 2026, 23:09 UTC

Market Talk

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20. apr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Aims for Acquisition to Be Completed by End-2026

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Acquisition Would Be for A$175 Million

20. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20. apr 2026, 21:38 UTC

Market Talk

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20. apr 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20. apr 2026, 21:24 UTC

Market Talk

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20. apr 2026, 21:24 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 21:13 UTC

Tulu

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20. apr 2026, 21:10 UTC

Tulu

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20. apr 2026, 21:09 UTC

Tulu

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20. apr 2026, 21:08 UTC

Tulu

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20. apr 2026, 21:07 UTC

Tulu

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20. apr 2026, 21:05 UTC

Tulu

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20. apr 2026, 21:05 UTC

Tulu

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Muud aktsiad sektorist

MDT

Medtronic PLC

85.26

A

Agilent Technologies Inc

120.85

VEEV

Veeva Systems Inc

168.97

HQY

HealthEquity Inc

86.11

NEOG

Neogen Corp

9.63

Live chat